Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary objective of the study is to compare the pharmacokinetics of apatinib in subjects with impaired renal function and healthy subjects, to give dose recommendations for patients with impaired renal function.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| mild renal impairment | Experimental |
| |
| moderate remal impairment | Experimental |
| |
| normal renal impairment | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Apatinib Mesylate | Drug | All the subjects will be administrated with 250mg apatinib on day 1 |
|
| Measure | Description | Time Frame |
|---|---|---|
| Cmax | Maximum plasma concentration | 0-96 hours |
| AUC0-t | Area under the plasma concentration versus time curve from zero to 96h | 0-96 hours |
| AUC0-∞ | Area under the plasma concentration versus time curve from zero to infinity | 0-96 hours |
Not provided
Not provided
Inclusion Criteria:
for subjects with impaired renal function
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Yuya Wang | Contact | 13918749176 | wangyuya@hrglobe.cn |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C553458 | apatinib |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided